Healthcare Services
Valuation | |
|---|---|
| Market Cap | 23.81 kCr |
| Price/Earnings (Trailing) | 44.86 |
| Price/Sales (Trailing) | 8.61 |
| EV/EBITDA | 28.28 |
| Price/Free Cashflow | 50.26 |
| MarketCap/EBT | 35.94 |
| Enterprise Value | 23.69 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | -1.7% |
| Price Change 1M | 1.7% |
| Price Change 6M | -17.7% |
| Price Change 1Y | 8.4% |
| 3Y Cumulative Return | 13.1% |
| 5Y Cumulative Return | 1.8% |
| 7Y Cumulative Return | 15.6% |
| 10Y Cumulative Return | 12.6% |
| Revenue (TTM) |
| 2.77 kCr |
| Rev. Growth (Yr) | 10% |
| Earnings (TTM) | 533.1 Cr |
| Earnings Growth (Yr) | -6.8% |
Profitability | |
|---|---|
| Operating Margin | 25% |
| EBT Margin | 24% |
| Return on Equity | 22.01% |
| Return on Assets | 18.02% |
| Free Cashflow Yield | 1.99% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -303.1 Cr |
| Cash Flow from Operations (TTM) | 568.8 Cr |
| Cash Flow from Financing (TTM) | -334 Cr |
| Cash & Equivalents | 116.1 Cr |
| Free Cash Flow (TTM) | 524.5 Cr |
| Free Cash Flow/Share (TTM) | 62.61 |
Balance Sheet | |
|---|---|
| Total Assets | 2.96 kCr |
| Total Liabilities | 537.1 Cr |
| Shareholder Equity | 2.42 kCr |
| Current Assets | 1.52 kCr |
| Current Liabilities | 433.2 Cr |
| Net PPE | 429.3 Cr |
| Inventory | 50.2 Cr |
| Goodwill | 548.1 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.00 |
| Debt/Equity | 0.00 |
| Interest Coverage | 29.53 |
| Interest/Cashflow Ops | 28.09 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 13 |
| Dividend Yield | 0.91% |
| Shares Dilution (1Y) | 0.20% |
| Shares Dilution (3Y) | 0.50% |
Technicals: Bullish SharesGuru indicator.
Growth: Good revenue growth. With 34.9% growth over past three years, the company is going strong.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 19%.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Size: Market Cap wise it is among the top 20% companies of india.
Momentum: Stock has a weak negative price momentum.
Technicals: Bullish SharesGuru indicator.
Growth: Good revenue growth. With 34.9% growth over past three years, the company is going strong.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 19%.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Size: Market Cap wise it is among the top 20% companies of india.
Momentum: Stock has a weak negative price momentum.
Investor Care | |
|---|---|
| Dividend Yield | 0.91% |
| Dividend/Share (TTM) | 13 |
| Shares Dilution (1Y) | 0.20% |
| Earnings/Share (TTM) | 31.67 |
Financial Health | |
|---|---|
| Current Ratio | 3.51 |
| Debt/Equity | 0.00 |
Technical Indicators | |
|---|---|
| RSI (14d) | 56.46 |
| RSI (5d) | 17.84 |
| RSI (21d) | 48 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Sell |
| RSI Signal | Hold |
| RSI5 Signal | Buy |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal |
Summary of Dr. Lal Pathlabs's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
During the Q3 FY26 earnings call, management provided a positive outlook reflecting growth amidst evolving healthcare dynamics in India. The focus is on transitioning diagnostics from episodic illness-driven measures to a continuous component of long-term health management. Key strategies highlighted include:
Launch of Sovaaka: A personalized preventive healthcare platform aimed at addressing the rising demand for personalized care. This represents a shift from traditional disease detection to science-led prevention.
Expansion of Testing Capabilities: Management is strengthening high-end diagnostic offerings, particularly in oncology and genomics, and continues to invest in reference labs and collaborations with global technology partners.
Market Penetration: A scalable franchisee-led model is being utilized to enhance presence in Tier 3 and Tier 4 markets, ensuring improved diagnostic access in semi-urban and rural areas.
Financially, Dr. Lal PathLabs reported a revenue of Rs.660 crore for Q3 FY26, up 10.6% YoY, and Rs.2,060 crore for the nine-month period, reflecting a growth of 10.8%. Patient volume growth was 2.7% in Q3 with a YTD growth of 4.4%. Notably, despite challenges, sample growth remains robust at 9.6%.
Key metrics included:
Management emphasized that with a focus on organic growth, they aim for a growth trajectory of 11% to 12% annually moving forward, reflecting confidence in future prospects bolstered by market expansion and innovative offerings.
Understand Dr. Lal Pathlabs ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| Arvind Lal | 30.16% |
| Vandana Lal | 19.2% |
| Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund | 3.93% |
| Uti-Flexi Cap Fund | 2.4% |
| Invesco Oppenheimer International Growth Fund | 2.38% |
| Nippon Life India Trustee Ltd-A/C Nippon India Multi Cap Fund | 2.34% |
| Anjaneya Lal |
Detailed comparison of Dr. Lal Pathlabs against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSP | Apollo Hospitals Enterprises | 1.1 LCr | 24.42 kCr | +5.30% | +21.50% | 60.78 | 4.48 | - | - |
| FORTIS | Fortis Healthcare | 69.14 kCr |
Comprehensive comparison against sector averages
LALPATHLAB metrics compared to Healthcare
| Category | LALPATHLAB | Healthcare |
|---|---|---|
| PE | 44.16 | 45.48 |
| PS | 8.47 | 6.27 |
| Growth | 11.1 % | 17.6 % |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
LALPATHLAB vs Healthcare (2021 - 2026)
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years
1. Question by Prakash Kapadia: "At a time when industry revenues have been growing in the 7%-8% range, what is leading to our growth trend of 10.5%, and how is Swasthfit performing in Tier 2 and Tier 3 markets?"
Answer: "We're focusing on organic growth, aiming for 11%-12% this year. Our stability reflects a strategic plan to rebuild momentum, allowing for future growth. Swasthfit is indeed expanding into smaller towns and gaining traction, showing positive acceptance and even receiving doctor recommendations, which aids our growth."
2. Question by Vivek Agrawal: "Can you break down the patient volumes and seasonal impacts on Q3 revenues?"
Answer: "We typically don't disclose specific seasonal breakdowns, but our seasonal fever portfolio was lower than expected, impacting overall patient volumes this quarter. However, we believe in a steady upward trajectory over the long term."
3. Question by Anshul Agrawal: "Will 9-month margins around 29% be sustainable going forward, and can you share insights on the advanced radiology pilot?"
Answer: "We expect margins around 27%-28%, factoring in the labor code impact this quarter. Regarding radiology, we're piloting centers in Delhi and monitoring performance closely for future expansion."
4. Question by Raman KV: "What are the total test volumes, and how does Swasthfit impact margins?"
Answer: "We performed 22.2 million samples this quarter. Swasthfit's bundle offers higher realization, but we provide discounts affecting margins. Overall, it's not margin-dilutive, as we gain operating leverage."
5. Question by Saion Mukherjee: "What factors will drive increased patient volume growth, and are acquisitions a possibility?"
Answer: "Increased geographic coverage through new testing labs is key for growth. We're also exploring inorganic opportunities, focusing on mid-sized or top players in strategic markets to expand our reach."
6. Question by Shyam Srinivasan: "Are we expecting RPP growth to exceed 11%-12% in the future?"
Answer: "We aim for 11%-12% this financial year but aspire to exceed this as our baseline. Price adjustments will depend on both internal costs and competitive conditions."
7. Question by Surya Patra: "What sets Sovaaka apart from Swasthfit, and is it scalable beyond NCR?"
Answer: "Sovaaka focuses on preventive wellness through an integrated model, differing from Swasthfit's pathology-led structure. We're assessing scalability based on initial center performance but envision expansion beyond NCR."
8. Question by Lokesh Manik: "Will Sovaaka operate as a direct-to-customer model, or will it involve clinicians?"
Answer: "Sovaaka primarily targets preventive wellness and will include clinician referrals. It's company-owned, ensuring quality control, and scaling decisions will depend on the initial outcomes and market response."
These questions encapsulate key concerns about growth trajectories, operational efficiencies, and future outlooks for Dr. Lal PathLabs, with management providing detailed and reassuring responses.
| 2.02% |
| Archana Lal Erdmann | 1.84% |
| Sbi Large & Midcap Fund | 1.65% |
| Smallcap World Fund, Inc | 1.59% |
| The Brown Capital Management International Small Company Fund | 1.41% |
| Tata Balanced Advantage Fund | 1.4% |
| Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Flexi Cap Fund | 1.37% |
Distribution across major stakeholders
Distribution across major institutional holders
| 8.84 kCr |
| +2.10% |
| +51.60% |
| 71.99 |
| 7.82 |
| - |
| - |
| VIJAYA | Vijaya Diagnostic Centre | 10.36 kCr | 792.02 Cr | +2.10% | +9.50% | 64.88 | 13.09 | - | - |
| METROPOLIS | Metropolis Healthcare | 10.04 kCr | 1.59 kCr | +1.70% | +15.20% | 59.53 | 6.31 | - | - |
| THYROCARE | Thyrocare Tech | 6.48 kCr | 809.52 Cr | -12.90% | +68.70% | 46.89 | 8 | - | - |
| -24.6% |
| 154 |
| 204 |
| 181 |
| 153 |
| 138 |
| 183 |
| Exceptional items before tax | - | -30.1 | 0 | 0 | 0 | 0 | 0 |
| Total profit before tax | -39.4% | 124 | 204 | 181 | 153 | 138 | 183 |
| Current tax | -15.2% | 40 | 47 | 45 | 39 | 40 | 48 |
| Deferred tax | -345.2% | -6.6 | 4.1 | 2.1 | -41.4 | 0.7 | 3.9 |
| Total tax | -36% | 33 | 51 | 47 | -2.1 | 40 | 52 |
| Total profit (loss) for period | -40.4% | 91 | 152 | 134 | 156 | 98 | 131 |
| Other comp. income net of taxes | -240% | 0.3 | 1.5 | -0.9 | -2.6 | -0.1 | -0.8 |
| Total Comprehensive Income | -40.5% | 92 | 154 | 133 | 153 | 98 | 130 |
| Earnings Per Share, Basic | -44.9% | 5.42 | 9.025 | 7.94 | 9.285 | 5.8 | 7.76 |
| Earnings Per Share, Diluted | -44.9% | 5.41 | 95 | 7.925 | 9.27 | 5.79 | 7.74 |
| -19.2% |
| 22 |
| 27 |
| 34 |
| 28 |
| 15 |
| 15 |
| Depreciation and Amortization | 77.3% | 134 | 76 | 82 | 75 | 70 | 68 |
| Other expenses | 18.3% | 772 | 653 | 603 | 596 | 452 | 427 |
| Total Expenses | 21.9% | 1,842 | 1,511 | 1,425 | 1,466 | 1,168 | 1,028 |
| Profit Before exceptional items and Tax | 20.4% | 621 | 516 | 391 | 459 | 374 | 303 |
| Total profit before tax | 20.4% | 621 | 516 | 391 | 459 | 374 | 303 |
| Current tax | 18.2% | 163 | 138 | 101 | 118 | 98 | 80 |
| Deferred tax | -475.7% | -39.3 | -6 | -3 | -2.7 | -4.5 | -0.7 |
| Total tax | -6.1% | 124 | 132 | 98 | 115 | 94 | 80 |
| Total profit (loss) for period | 29.5% | 497 | 384 | 292 | 344 | 280 | 223 |
| Other comp. income net of taxes | -253.8% | -3.6 | -0.3 | 1.9 | -1.3 | -0.7 | -1.1 |
| Total Comprehensive Income | 28.7% | 494 | 384 | 294 | 343 | 279 | 222 |
| Earnings Per Share, Basic | 30.4% | 29.85 | 23.125 | 17.64 | 20.805 | 16.965 | 13.545 |
| Earnings Per Share, Diluted | 30.4% | 29.805 | 23.09 | 17.585 | 20.74 | 16.925 | 13.52 |
| 414 |
| 321 |
| 282 |
| 294 |
| 296 |
| 345 |
| Capital work-in-progress | 540% | 17 | 3.5 | 1.4 | 4 | 9.7 | 3 |
| Investment property | 0% | 33 | 33 | 34 | 34 | 34 | 0 |
| Goodwill | 0% | 471 | 471 | 1.1 | 1.1 | 1.1 | 1.1 |
| Non-current investments | 0% | 114 | 114 | 1,073 | 1,073 | 1,072 | 1,072 |
| Loans, non-current | - | 0 | 0 | 0 | 0 | 0 | 0.1 |
| Total non-current financial assets | -1.6% | 191 | 194 | 1,082 | 1,093 | 1,086 | 1,097 |
| Total non-current assets | 6.3% | 1,428 | 1,344 | 1,466 | 1,495 | 1,500 | 1,510 |
| Total assets | 8.9% | 2,854 | 2,621 | 2,579 | 2,415 | 2,392 | 2,320 |
| Borrowings, non-current | - | 0 | 0 | 0 | 0 | 42 | 83 |
| Total non-current financial liabilities | -3.1% | 95 | 98 | 86 | 91 | 152 | 198 |
| Total non-current liabilities | -3.1% | 95 | 98 | 86 | 91 | 152 | 198 |
| Borrowings, current | - | 0 | 0 | 42 | 83 | 83 | 153 |
| Total current financial liabilities | 0.7% | 302 | 300 | 334 | 349 | 345 | 380 |
| Provisions, current | 15.2% | 39 | 34 | 22 | 31 | 27 | 23 |
| Current tax liabilities | 115.4% | 29 | 14 | 29 | 13 | 25 | 0.5 |
| Total current liabilities | 7.8% | 418 | 388 | 419 | 424 | 430 | 432 |
| Total liabilities | 5.3% | 513 | 487 | 505 | 516 | 582 | 630 |
| Equity share capital | 0% | 84 | 84 | 84 | 84 | 84 | 83 |
| Total equity | 9.7% | 2,341 | 2,134 | 2,074 | 1,900 | 1,810 | 1,690 |
| Total equity and liabilities | 8.9% | 2,854 | 2,621 | 2,579 | 2,415 | 2,392 | 2,320 |
| 695 |
| 603 |
| 527 |
| 541 |
| - |
| - |
| Income taxes paid (refund) | 24.2% | 155 | 125 | 99 | 117 | - | - |
| Net Cashflows From Operating Activities | 13% | 540 | 478 | 428 | 424 | - | - |
| Cashflows used in obtaining control of subsidiaries | 100% | 1 | 0.8 | 22 | 942 | - | - |
| Proceeds from sales of PPE | -50% | 0.7 | 0.8 | 0 | 0.4 | - | - |
| Purchase of property, plant and equipment | -4.5% | 43 | 45 | 32 | 63 | - | - |
| Proceeds from sales of investment property | - | 0 | 0 | 0.1 | 0 | - | - |
| Purchase of intangible assets | 150% | 9.5 | 4.4 | 6.3 | 5.5 | - | - |
| Dividends received | 945.5% | 24 | 3.2 | 12 | 1.6 | - | - |
| Interest received | 62.9% | 58 | 36 | 27 | 48 | - | - |
| Other inflows (outflows) of cash | -886.8% | -321.6 | 42 | -268.1 | 460 | - | - |
| Net Cashflows From Investing Activities | -1048.4% | -293 | 32 | -288.6 | -448.5 | - | - |
| Proceeds from issuing shares | - | 13 | 0 | 0 | 0 | - | - |
| Proceeds from exercise of stock options | -140% | 0 | 3.5 | 0.9 | 0.1 | - | - |
| Proceeds from borrowings | - | 0 | 0 | 0 | 345 | - | - |
| Repayments of borrowings | -46.1% | 83 | 153 | 109 | 0 | - | - |
| Payments of lease liabilities | 18.5% | 33 | 28 | 19 | 59 | - | - |
| Dividends paid | 0% | 200 | 200 | 99 | 116 | - | - |
| Interest paid | -19.2% | 22 | 27 | 44 | 28 | - | - |
| Other inflows (outflows) of cash | - | 0 | 0 | 0.1 | 0 | - | - |
| Net Cashflows from Financing Activities | 19.5% | -324.8 | -403.9 | -270 | 142 | - | - |
| Net change in cash and cash eq. | -175% | -77.8 | 106 | -131 | 117 | - | - |